The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs’ proprietary Oral Thin Film technology platform, ThinOral
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
TFOS is indicated for the treatment of pulmonary arterial hypertension
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Subscribe To Our Newsletter & Stay Updated
